AstraZeneca is opening a new cell therapy manufacturing base and innovation center in Shanghai, becoming the first multinational pharma in China with full CAR-T capabilities. The facilities will support research, development, and production of therapies like AZD0120, a dual-target CAR-T treatment for cancer and autoimmune diseases. The expansion is part of a $15 billion investment through 2030 and includes a collaboration program with UK universities and partners to boost innovation, startups, and international commercialization.
(Source: Reuters)